title: The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
abstract: OBJECTIVE
  The new Abl tyrosine kinase inhibitor imatinib (imatinib mesylate, STI571) is very effective in the treatment of patients with chronic myeloid leukemia (CML). It induces complete hematologic control in >90% of patients with CML in chronic phase and preliminary data suggest that the incidence of complete cytogenetic remission may exceed 60% in previously untreated patients, though its capacity to prolong life in comparison with other agents has not yet been clearly established. It is also active in the management of patients in advanced phases of CML.
  
  
  METHODS
  We present here provisional indications for the use of imatinib in CML patients and give details of the dosage regimens we have used and side-effects we have encountered.
  
  
  CONCLUSIONS
  It is likely that the optimal usage of this important new agent will become better defined as more experience is gained.
authors.forename: David
authors.initials: D
authors.lastname: Marin
authors.forename: Sarah
authors.initials: S
authors.lastname: Marktel
authors.forename: Marco
authors.initials: M
authors.lastname: Bua
authors.forename: Lorraine
authors.initials: L
authors.lastname: Armstrong
authors.forename: John M
authors.initials: JM
authors.lastname: Goldman
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.forename: Eduardo
authors.initials: E
authors.lastname: Olavarria
mesh_terms: D001549:Benzamides; D018450:Disease Progression; D004347:Drug Interactions; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate